COMP <GO>
JNJ vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Johnson & Johnson (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: JNJ 4
— LLY 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JNJ VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JNJ | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.90% | 83.64% | -15.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.50% | 32.36% | -6.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 36.4x | -17.92 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.97% | 2.30% | +0.67 | JNJ | /fcf-yield <GO> |
| Operating Margin | 34.70% | 40.21% | -5.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 28.50% | 31.90% | -3.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.00% | 45.51% | -39.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.59 | 9.29 | -3.70 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 77.9 | -17.53 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 26.3x | -3.25 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.49B | $1.33T | -$671.92B | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JNJ REV | LLY REV | JNJ GROSS % | LLY GROSS % | JNJ FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $94.19B | $65.18B | 67.9% | 83.0% | $19.70B | $16.81B |
| FY 2024 | $88.82B | $45.04B | 69.1% | 81.3% | $19.84B | $8.82B |
| FY 2023 | $85.16B | $34.12B | 44.0% | 79.3% | $18.96B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JNJ // BETA 1.08
LLY // BETA 0.51